Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)

M Capobianco; S Malucchi; A di Sapio; F Gilli; A Sala; R Bottero; F Marnetto; C Doriguzzi Bozzo; A Bertolotto

doi:10.1007/s10072-007-0823-z

Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)

Neurol Sci. 2007 Aug;28(4):209-11. doi: 10.1007/s10072-007-0823-z. Epub 2007 Aug 10.

Authors

M Capobianco¹, S Malucchi, A di Sapio, F Gilli, A Sala, R Bottero, F Marnetto, C Doriguzzi Bozzo, A Bertolotto

Affiliation

¹ Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica - ASO S. Luigi Gonzaga, Regione Gonzole 10, I-10043, Orbassano (TO), Italy. sclerosi.multipla@sanluigi.piemonte.it

PMID: 17690854
DOI: 10.1007/s10072-007-0823-z

Abstract

We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Brain / pathology
Female
Humans
Immunologic Factors / therapeutic use*
Magnetic Resonance Imaging / methods
Neuromyelitis Optica / drug therapy*
Neuromyelitis Optica / pathology
Neuromyelitis Optica / physiopathology*
Rituximab
Spinal Cord / pathology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab